Archived Investigations
DexCom, Inc. (NasdaqGS: DXCM)
DexCom and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On September 18, 2025, Hunterbrook published a report addressing the Company, entitled “Dexcom’s Fatal Flaws,” revealing that issues and health risks posed by the Company’s adulterated G7 devices were more severe and widespread than previously disclosed, citing FDA documents it had procured via a Freedom of Information Act request, as well as various comments from doctors, patients and their families, and former DexCom employees. Specifically, the Hunterbrook report found that “G7 users have been hospitalized and died” following inaccurate glucose readings, linking these deadly incidents to adulterated G7 devices and the Company’s willingness to cut corners to meet margins.
On this news, the price of DexCom’s shares fell $8.99 per share, or 11.76%, over the following two trading sessions, to close at $67.45 per share on September 19, 2025.
The first-filed case is Prime v. DexCom, Inc., et al., No. 25-cv-08912. A subsequent case, Oakland County Employees Retirement System v. DexCom, Inc., et al., No. 25-cv-09370, expanded the class period.